CD248 and cancer: Based on the important role of stroma in supporting tumor growth and the activity of endosialin/TEM-1 in supporting tumor stromal cell functions, clinical studies using a humanized monoclonal antibody called ontuxizumab (MORAb-004) that can perturb endosialin/TEM-1 biology are currently being conducted to determine the safety and clinical activity in a variety of cancer types [27].